Free Trial
→ I'm handing you this one free (From Behind the Markets) (Ad)tc pixel
NASDAQ:ADIL

Adial Pharmaceuticals Q3 2026 Earnings Date & Estimates

Adial Pharmaceuticals logo
$4.88 -0.17 (-3.45%)
Closing price 10/28/2026
Extended Trading
$4.88 0.00 (0.00%)
As of 10/28/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Adial Pharmaceuticals is estimated to report Q3 2026 earnings on Wednesday, November 18, 2026. The conference call is scheduled for November 20, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Adial Pharmaceuticals in Q3 2026

Adial Pharmaceuticals is expected to post earnings of -$0.1750 per share. In the same quarter a year earlier Adial Pharmaceuticals reported -$2.00 per share. Adial Pharmaceuticals last reported on August 14, 2026, posting -$11.25 per share and missing the -$1.0325 consensus estimate. Adial Pharmaceuticals has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.1750
Prior-Year EPS
-$2.00

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$11.25 (Missed by -$10.2175)
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Adial Pharmaceuticals Q3 2026 Earnings FAQ

Adial Pharmaceuticals (NASDAQ:ADIL) is estimated to report Q3 2026 earnings on Wednesday, November 18, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Adial Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Friday, November 20, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Adial Pharmaceuticals to post earnings of -$0.1750 per share for Q3 2026.

Adial Pharmaceuticals Earnings Headlines

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis
October 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/28/3390720/0/en/adial-pharmaceuticals-announces-name-change-to-azora-therapeutics-and-new-executive-team-focused-on-advancing-at177-an-oral-colon-targeted-ahr-agonist-for-ulcerative-colitis.html
Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer
October 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/adial-pharmaceuticals-announces-planned-appointment-120000499.html
My prediction for December 8th
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
November 10 at 1:00 AM  |  Behind the Markets (Ad)
Adial Pharmaceuticals to appoint Celia Economides as CFO
October 26, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/adial-pharmaceuticals-to-appoint-celia-economides-as-cfo/ar-AA2g5LXw
Adial Pharmaceuticals, Inc. Announces Appointment of David Rubenstein, M.D., Ph.D. as Chief Scientist
October 16, 2026  |  marketscreener.comM
Adial Pharmaceuticals Appoints AhR Drug Development Veteran David Rubenstein as Chief Scientist to Advance AT177 for Ulcerative Colitis
October 16, 2026  |  quiverquant.comQ
See More Adial Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adial Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adial Pharmaceuticals and other key companies, straight to your email.

About Adial Pharmaceuticals

Adial Pharmaceuticals (NASDAQ:ADIL) is a clinical-stage biotechnology company focused on developing therapeutics for addiction and related disorders. The company’s primary product candidate is AD04, an investigational formulation of ondansetron, a serotonin 5-HT3 receptor antagonist, being developed as a pharmacogenetically targeted treatment for alcohol use disorder.

AD04 is designed for people with alcohol use disorder who have specific genetic characteristics that may influence treatment response. Adial’s development approach combines pharmaceutical treatment with genetic testing to identify potentially responsive patient populations. The company has also evaluated the broader potential of its technology and drug-development programs in other addiction-related indications, although its principal focus has been alcohol use disorder.

Adial Pharmaceuticals was founded around research conducted by the late Dr. Bankole Johnson, an addiction-medicine researcher whose work formed the scientific basis for AD04. The company is headquartered in Charlottesville, Virginia, and its development activities are directed toward addressing unmet medical needs in addiction treatment. Cary D. Claiborne has served as the company’s chief executive officer.

View Adial Pharmaceuticals Profile
Earnings Tools